Specific Targeting of Memory-like NK Cells to CD123 and CD33 Enhances Killing of Patient-Derived Acute Myeloid Leukemia

Key Points

• Killing efficacy was significantly enhanced by specifically targeting CD123 and CD33.
• Memory-like NK cells showed increased activation when directed towards these leukemia markers.
• Assessment involved patient-derived cells from acute myeloid leukemia samples, verifying clinical relevance.
• This approach may enable more effective therapies, but further studies are needed to confirm results.